HHS Announces Home Care Initiatives

Managed Care Cast Presents: Insights Into Precision Medicine in NSCLC

MRD is not accepted by regulators as a surrogate endpoint, but a commenter at the American Society of Hematology plenary session said one is needed.

November 30th 2023

Worsening Severity of AD in Children Associated With Increased Comorbidity Onset Risk

In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.

Listen

Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 2

Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort.

November 21st 2023

Direct-Mail Self-Sampling Increased Cervical Cancer Screening Among Due, Overdue Patients

In part 2 of this 2-part podcast, a panel of experts discusses implementation biosimilars in biologic-naïve patients, auto-substitution, and more.

Listen

FDA Approves bluebird bio's Lovo-Cel Gene Therapy for Sickle Cell Disease

Although direct-mail self-sampling significantly increased cervical cancer screening, the opt-in approach only minimally increased screening.

Adding Isatuximab to Carfilzomib-based Combo for Those Newly Diagnosed With Multiple Myeloma Boosts MRD Negativity Rates

The decision was supported by efficacy data from 36 patients from the ongoing phase 1/2 HGB-206 trial (NCT02140554) and 2 patients in the phase 3 HGB-210 trial (NCT04293185). It was the second approval from FDA for a gene therapy for sickle cell disease.

Related Content

December 11th 2023

Managed Care Cast Presents: Insights Into Precision Medicine in NSCLC

MRD is not accepted by regulators as a surrogate endpoint, but a commenter at the American Society of Hematology plenary session said one is needed.

November 30th 2023

Worsening Severity of AD in Children Associated With Increased Comorbidity Onset Risk

In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.

Listen

Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 2

Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort.

November 21st 2023

Direct-Mail Self-Sampling Increased Cervical Cancer Screening Among Due, Overdue Patients

In part 2 of this 2-part podcast, a panel of experts discusses implementation biosimilars in biologic-naïve patients, auto-substitution, and more.

Listen

FDA Approves bluebird bio's Lovo-Cel Gene Therapy for Sickle Cell Disease

Although direct-mail self-sampling significantly increased cervical cancer screening, the opt-in approach only minimally increased screening.